Scarica l'app Stockscreener
7.51
4.74%
0.34
Dopo l'orario di chiusura:
7.53
0.02
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$7.17
Aprire:
$7.35
Volume 24 ore:
2.71M
Relative Volume:
1.33
Capitalizzazione di mercato:
$2.78B
Reddito:
$9.47B
Utile/perdita netta:
$-178.00M
Rapporto P/E:
-15.65
EPS:
-0.48
Flusso di cassa netto:
$1.01B
1 W Prestazione:
+30.38%
1M Prestazione:
+18.45%
6M Prestazione:
+21.92%
1 anno Prestazione:
+35.80%
Intervallo 1D:
$7.215
$7.77
Intervallo di 1 settimana:
$5.745
$7.77
Portata 52W:
$4.25
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Nome
Bausch Health Companies Inc
Settore
Telefono
514-744-6792
Indirizzo
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Confronta BHC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
7.51 | 2.59B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
153.06 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 46.20B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.70 | 42.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.54 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.06 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-06-16 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Downgrade | Truist | Buy → Hold |
| 2022-07-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Ripresa | JP Morgan | Overweight |
| 2021-03-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-24 | Iniziato | Citigroup | Buy |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Iniziato | Goldman | Neutral |
| 2019-10-25 | Iniziato | Cowen | Outperform |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-08-15 | Aggiornamento | TD Securities | Hold → Buy |
| 2019-07-19 | Iniziato | Wolfe Research | Outperform |
| 2019-06-11 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-01-02 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Aggiornamento | Piper Jaffray | Underweight → Neutral |
Mostra tutto
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting - MSN
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health - The Malaysian Reserve
Form PRE 14A Bausch Health Companies For: Oct 07 - StreetInsider
Durect and Bausch Health Merger on Track to Close in Q3 - AInvest
Bausch Health's Durect Acquisition: Strategic Valuation and Risk Mitigation in Biopharma M&A - AInvest
Biotech DURECT Gets $63M Buyout Offer from Bausch Health with $350M Future Payment Potential - Stock Titan
IBS in America: Despite advances, IBS remains a burden for many millions - Benzinga
Why Bausch Health Stock Surged By Nearly 20% (NYSE:BHC) - Seeking Alpha
Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance - MSN
Bausch Health Companies Inc. shares fall 1.65% premarket as TSX steadies with tech stocks rising. - AInvest
United States Epilepsy Drugs Market Trends and Company - GlobeNewswire
Is This a Bottoming Phase for Bausch Health Companies Inc.Intraday Trend Analysis for Fast Gains Released - metal.it
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment - MSN
Is Bausch Health Companies Inc. Forming a Consolidation BaseShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Saudi Arabia OTC Artificial Tears Market Forecast and - GlobeNewswire
Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical - Yahoo Finance
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners - The Daily Corinthian
Bausch Health's $100K GI Health Scholarship Program Empowers 10 Students Despite Medical Challenges - Stock Titan
Bausch Health Companies Inc. shares fall 2.95% intraday as Toronto stocks climb to fresh highs. - AInvest
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease - biomb.ca
Bausch Health Companies Inc. shares rise 2.68% intraday after Viatris Inc. appoints David Simmons to its Board of Directors. - AInvest
Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - Barchart.com
Saudi Arabia Vision Care Market Forecast and Company - GlobeNewswire
Saudi Arabia Vision Care Market Forecast and Company Analysis Report 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant, Paragon Vision Science, Menicon - Yahoo Finance
Is Bausch Health Companies Inc. a growth stock or a value stockFree Daily Trading Room Entry - Jammu Links News
What are the technical indicators suggesting about Bausch Health Companies Inc.Fastest-growing stock picks - Jammu Links News
What are analysts’ price targets for Bausch Health Companies Inc. in the next 12 monthsBuild a diversified portfolio for stability - Jammu Links News
What institutional investors are buying Bausch Health Companies Inc. stockBuild a winning portfolio with smart picks - Jammu Links News
What analysts say about Bausch Health Companies Inc. stockInvest confidently with professional guidance - Jammu Links News
Does Bausch Health Companies Inc. stock perform well during market downturnsGet timely alerts on market opportunities - Jammu Links News
How does Bausch Health Companies Inc. compare to its industry peersConsistently superior profits - Jammu Links News
What catalysts could drive Bausch Health Companies Inc. stock higher in 2025Track high-yield stocks before they peak - Jammu Links News
Lacklustre Performance Is Driving Bausch Health Companies Inc.'s (NYSE:BHC) 25% Price Drop - 富途牛牛
How many analysts rate Bausch Health Companies Inc. as a “Buy”Discover market opportunities with real-time data - Jammu Links News
What is the dividend policy of Bausch Health Companies Inc. stockRapid capital growth - Jammu Links News
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Inc. Attempts Reversal From Key SupportNews Based Entry Opportunity Alerts Detected - metal.it
Real Time Data Flags Unusual Activity in Bausch Health Companies Inc.Profit Target Stock Opportunity Monitor Activated - metal.it
Bausch Health to acquire liver drug developer Durect for $1.75 per share - MSN
Bausch Health Companies Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bausch Health Companies Inc. Bounces Off Moving Average SupportFast Return Equity Trade Forecast Points to Small Caps - metal.it
Bausch Health to redeem ~$602M of outstanding notes due 2026 - MSN
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat - MSN
How strong is Bausch Health Companies Inc. company’s balance sheetBest Dividend Tips With High Returns - Jammu Links News
Bausch Health’s Earnings Climb, But The Road Ahead Stays Cloudy - Finimize
Bausch Health Companies Inc. SEC 10-Q Report - TradingView
Bausch: Q2 Earnings Snapshot - Connecticut Post
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health - Yahoo Finance
Bausch Health Companies Inc (BHC) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Bausch Health Companies Inc Azioni (BHC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):